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TRANSGENIC APPROACH TO HEPATITIS B 
VIRUS LIVER DAMAGE 
Moriyama T,  Gulhot S, Klopchin K, Moss B, Pinkert CA, 
Palmiter RD, Brinster RL, et al. Immunobiology and 
pathogenesis of hepatocellular injury in hepatitis B virus 
transgenic mice. Science 1990;248:361-64. 
EDITORS ABSTRACT 
This study investigates the role of the immune 
system in the pathogenesis of hepatic injury during 
hepatitis B virus infection. A transgenic mouse line 
containing the gene sequences for the hepatitis B virus 
envelope region (pre-S1, pre-S2, and HBs Ags) ligated 
to mouse albumin regulatory sequences was developed. 
Mice of this lineage did not contract spontaneous liver 
disease and were immunologically tolerant to pre-S 
and HBs Ags. Nontransgenic mice of the same lineage 
were immunized with a recombinant vaccinia virus 
containing the coding region for the HBs polypeptide. 
Spleen cells from immunized mice were transferred 
into the transgenic mice. The recipient transgenic 
mice exhibited prompt falls in serum HBsAg, a p  
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pearance of serum anti-HBsAg and biphasic patterns 
of serum ALT elevation. The first rise in serum ALT 
(3 to 7 days after spleen cell transfer) appeared to be 
due to antibody-mediated cell injury because it could 
be reproduced by administration of serum from immu- 
nized, nontransgenic mice to transgenic mice. The 
second rise in ALT, at 14 to 21 days, occurred long after 
disappearance of serum HBsAg and was associated 
with histological evidence of liver cell necrosis and 
infiltration of the liver by lymphocytes. In other 
experiments, the pattern of delayed injury was 
reproduced by transfer of specific cytotoxic Lyt 2 +  
(CD8) T cells from immunized nontransgenic mice to 
transgenic mice, suggesting a role for cytotoxic T 
lymphocyte-mediated immune injury. Further studies 
using a cytotoxic T lymphocyte cell line specifically 
sensitized to HBsAg suggested that (a) cytotoxicity was 
specifically directed against cells that expressed a 
small region of the HBsAg; (b) cytotoxicity was mGor 
histocompatibility complex-restricted (i.e. cells ex- 
pressing HBsAg but not identical major histocompati- 
bility complex antigens were not killed); (c) cytotox- 
icity was enhanced if target cells were pretreated with 
y-interferon, which presumably enhances expression 
of mqjor histocompatibility complex antigens; and (d) 
cytotoxicity and liver cell injury could be reproduced 
in uiuo by transfer of HBsAg-directed cytotoxic T cell 
lines back into transgenic mice (which express hepa- 
titis B antigens). In summary, transgenic mice were 
raised that expressed HBV-encoded antigens at the 
hepatocyte surface in a form recognizable by both 
mdor histocompatibility complex class I-restricted 
cytotoxic T lymphocytes and envelope-specific anti- 
bodies. The resultant liver cell iqjury indicates that 
chronic HBV infection may be mediated by antigen- 
specific, cell-mediated responses. Finally, these studies 
also suggest a role (perhaps minor) for viral antibodies 
in hepatocyte injury. 
COMMENTS 
This study is the most recent in a series of important 
papers by Chisari and colleagues regarding mechanisms 
of HBV infection. It highlights the usefulness of trans- 
genic mice in exploring mechanisms of disease that have 
remained undefined for lack of an appropriate experi- 
mental model-in this case, the relative roles of direct 
viral cytotoxicity and immune-mediated cell injury in 
determining liver damage during acute and chronic HBV 
infections. A body of indirect evidence suggests that an 
immune response to HBV has a dominant role, including 
observations such as the lack of hepatic injury in many 
individuals chronically infected with HBV and the effect 
of treatment with immunosuppressive agents on en- 
hancing viral replication and suppressing hepatic injury. 
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The transgenic model permits the incorporation of DNA 
sequence coding for any given polypeptide into a mouse 
embryonic genome. If successful, the sequence is ex- 
pressed and processed in the test mouse in a manner 
similar to that of the native polypeptide. A promoter is 
required for expression of any gene, and the transgenic 
technique allows investigators to use either the endog- 
enous promoter of the gene under study or an exogenous 
promoter with desirable properties. For instance, this 
group of investigators previously had used the metal- 
lothionein promoter ligated to HBV genes, allowing 
them to induce gene expression in certain tissues at will 
by administering zinc orally. In this study, the albumin 
promoter was used, which directs tissue-specific gene 
expression in the liver, a pattern of expression more 
reflective of HBV infection in humans. The transgenic 
mouse is immunologically tolerant to the expressed 
polypeptide. This can be a drawback of the transgenic 
model because many pathological processes are me- 
diated by the host immune system. Chisari and co- 
workers, however, have used this property to attempt to 
distinguish between effects of the immune system and 
direct cytotoxic effects of HBV peptides. 
Chisari et al. first described transgenic mouse lines 
bearing the pre-S1, pre-S2, S and X coding regions in 
1985 (1). They were able to demonstrate mRNA tran- 
scripts for HBV proteins in liver, kidney, testis, heart 
and brain. HBsAg was found in serum and in numerous 
tissues, whereas the pre-S antigen was also found in 
liver. These animals did not exhibit clinical or histo- 
logical abnormalities, suggesting that HBsAg expression 
alone is not sufficient to cause injury. Immunization of 
these transgenic mice with human HBsAg failed to elicit 
an antibody response; as expected, these mice were 
immunologically tolerant. Chisari and his coworkers 
later extended these preliminary observations using an 
albumin promoter in conjunction with the HBV gene 
sequences that would make the envelope protein ex- 
pression more liver specific (2, 3). Transgenic lineages 
that expressed various amounts of HBsAg mRNA were 
selected for observation. The relative amount of large 
envelope protein to major envelope protein expressed 
also varied among the different transgenic lineages 
under observation. Envelope proteins are produced in at 
least three different sizes and denoted the major 
(traditional HBsAg), middle (pre-S2 and HBsAg) and 
large (pre-S1, pre-S2 and HBsAg) envelope proteins. 
Synthesis of each of these three proteins is thought to be 
determined by separate promoters and start codons. 
During HBV infection in man, the large envelope protein 
is synthesized in relatively greater amounts in early viral 
replication and is required for packaging of infectious 
virions. During chronic HBV infection, liver cells syn- 
thesize mainly the major envelope protein, which forms 
the numerous 22-nm spheres of noninfectious HBsAg 
seen in large numbers in serum. By ligating a complete 
sequence for envelope protein, including the pre-S1 and 
pre-S2 regions to an albumin promoter, Chisari and his 
colleagues created a series of transgenic mice that 
expressed all three envelope proteins (large, middle and 
major). When mice that expressed relatively large 
amounts of large envelope protein were examined for 
4 mo to 2 yr, the investigators observed development of 
(a) intracellular accumulation of large envelope protein 
in distorted endoplasmic reticulum (ER); (b) decreased 
hepatic secretion of the major envelope protein; (c) 
hepatic inflammation with infiltration of mononuclear 
cells and polymorphonuclear leukocytes; (d) hepatocel- 
lular necrosis and regeneration; (e) increased serum 
ALT levels; and (D tumor nodules resembling HCC (4). 
These observations are consistent with those of Persing, 
Varmus and Ganem (5) and others that suggest that 
synthesis of large envelope protein causes retention of 
HBsAg polypeptides in the ER, resulting in decreased 
hepatocyte secretion of these proteins. Chisari’s findings 
suggest that hangup of large amounts of protein in ER 
is directly toxic to hepatocytes, leading to hepatocellular 
injury, inflammation and HCC. Thus these previous 
studies support a direct cytotoxic role for hepatitis 
B-mediated liver injury, at least in cases where the large 
envelope protein is produced in large amounts. Whether 
this mechanism for liver injury actually occurs in 
humans with chronic HBV infection is unknown, but the 
association of chronic liver injury with impaired se- 
cretion of HBsAg should be testable because specific 
antibodies and cDNA probes for HBsAg polypeptides are 
available. 
In the study presented here, Chisari and colleagues 
reversed directions to use transgenic mice to test the 
alternate mechanism of hepatocellular injury - that of 
immune-mediated injury. An ideal model would be one 
that allows controlled introduction of individual compo- 
nents of the immune response. The authors accom- 
plished this feat with impressive results. They used 
transgenic mice that expressed large and major proteins 
under direction of an albumin promoter; however, the 
level of polypeptide production was low and these 
immunotolerant mice did not suffer spontaneous liver 
injury. The investigators then reconstituted part of an 
immune response to HBsAg by transferring long-lived 
spleen cells from nontransgenic mice immunized to the 
major (HBsAg) envelope protein into the transgenic 
mice. Clearance of serum HBsAg, liver cell injury and 
hepatic inflammation developed in transgenic mice that 
received spleen cells from immunized mice but not from 
unimmunized mice. Early clearance of serum HBsAg 
and liver cell injury may have been due to antiviral 
antibodies, whereas a second phase of prolonged injury 
appeared to be due to cell-mediated hepatocyte injury 
from specific cytotoxic T lymphocytes. T cells only killed 
cells expressing both parts of the major envelope pro- 
tein (HBsAg) and identical major histocompatibility 
complex (MHC) antigens, a pattern of classic MHC class 
I-restricted cytotoxic T lymphocyte killing in which T 
cells respond only when the specific antigen they are 
primed against is presented in conjunction with “self” 
recognition signals (MHC identical antigens). Cells that 
expressed HBsAg but not MHC antigens (such as 
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HBsAg-transfected mouse thymoma cells) were not 
killed. Hepatocyte killing was increased by treatment 
with y-interferon, which is thought to increase ex- 
pression of MHC antigens on hepatocytes. These obser- 
vations suggest that immune-mediated cell killing may 
contribute greatly to cell injury in hepatitis B infection 
and supports clinical findings that modulation of the 
immune response affects liver injury. 
How well does this remarkable animal model mirror 
the liver injury seen in humans with chronic hepatitis B? 
The answer is not known; however, observations from a 
number of investigators have shown the presence of nu- 
merous CD8+ T lymphocytes in areas of necrosis in 
infected human liver, some of which display signs of ac- 
tivation (6). Furthermore, human hepatocytes in areas 
of periportal necrosis display MHC class I and I1 an- 
tigens (7). Finally, some lymphocytes eluted from hepa- 
titis B-infected human liver tissue recognize HBsAg (8) 
or HBcAg (9). These findings, therefore, demonstrate 
that a t  least the elements of specific hepatitis B- 
directed, cytotoxic T cell-mediated hepatocyte injury in 
humans are in place. These results also provide a ra- 
tionale for the use of interferon or other immunomodu- 
lating agents in the treatment of chronic hepatitis B. 
It will be interesting as well to see future studies from 
this laboratory that will undoubtedly explore the rela- 
tionship between direct cytotoxic effects of hepatitis B 
and immune-mediated injury. These findings also open 
the way for further human studies to determine the 
basis for the varied response of humans to hepatitis B 
infection, ranging from resolved acute hepatitis B to 
chronic hepatitis B in healthy carriers to chronic active 
hepatitis B. 
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Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook 
JA, Trute A, Parker D, et al. Detection of hepatitis C 
viral sequences in blood donations by “nested poly- 




These studies used the polymerase chain reaction 
(PCR) to identify hepatitis C virus (HCV) RNA in 
clinical samples collected from patients with chronic 
liver disease or from blood donors. The relative role of 
this assay compared with detection of HCV antibodies 
in serum was evaluated. Weiner and colleagues found 
that 9 of 15 patients with non-A, non-B (NANB) chronic 
hepatitis and the only patient with cryptogenic cir- 
rhosis had persistent antibodies to a nonstructural 
protein of HCV (C100-3). Seven of the 10 antibody- 
positive patients had HCV RNA detected by a highly 
sensitive PCR assay; two of the antibody-negative 
patients also had HCV RNA. The pattern of viral RNA 
and antibody was evaluated in one patient with acute 
posttransfusion NANB hepatitis (PTNANB) and in 
three chimpanzees with acute infection. Viral RNA was 
detected early after infection and, in each case, before 
the appearance of antibody. In one chimpanzee, viral 
RNA disappeared when antibody became detectable. 
The authors conclude that most patients with chronic 
NANB liver disease have HCV infection. 
Garson and colleagues found that 6 of 1,100 donor 
blood units were repeatedly positive for antibodies to 
the C100-3 antigen (anti-Cl00-3). Only one of these six 
donor units was found to contain HCV RNA by a 
“nested PCR’ assay. Nested PCR refers to the use of 
two successive rounds of amplification, with the second 
round using primers internal to, or nested within, the 
original two primers. The positive donor unit was the 
only one of the six antibody-positive units to cause 
posttransfusion hepatitis in a recipient. Sera from 
three other confirmed cases of posttransfusion hepa- 
titis were evaluated and in each case one donor unit of 
blood was found to contain HCV RNA and anti-C100-3. 
The authors concluded that anti-C100-3 may not be a 
good predictor of infectivity in blood donors and that 
direct identification of viral RNA may be required. 
